Nanomedicine of tyrosine kinase inhibitors

Simple item page
dc.contributor.authorŠmídová, Veronikacs
dc.contributor.authorMichálek, Petrcs
dc.contributor.authorGoliášová, Zitacs
dc.contributor.authorEckschlager, Tomášcs
dc.contributor.authorHodek, Petrcs
dc.contributor.authorAdam, Vojtěchcs
dc.contributor.authorHeger, Zbyněkcs
dc.coverage.issue4cs
dc.coverage.volume11cs
dc.date.accessioned2021-05-05T14:54:45Z
dc.date.available2021-05-05T14:54:45Z
dc.date.issued2021-01-26cs
dc.description.abstractRecent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials. Some nanocarrier properties provide improvement of drug efficacy, reduce the incidence of adverse events, enhance drug bioavailability, helps to overcome the blood-brain barrier, increase drug stability or allow for specific delivery of TKIs to the diseased cells. Moreover, nanotechnology can bring new perspectives into combination therapy, which can be highly efficient in connection with TKIs. Lastly, nanotechnology in combination with TKIs can be utilized in the field of theranostics, i.e. for simultaneous therapeutic and diagnostic purposes. The review provides a comprehensive overview of advantages and future prospects of conjunction of nanotransporters with TKIs as a highly promising approach to anticancer therapy.en
dc.formattextcs
dc.format.extent1546-1567cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationTheranostics. 2021, vol. 11, issue 4, p. 1546-1567.en
dc.identifier.doi10.7150/thno.48662cs
dc.identifier.issn1838-7640cs
dc.identifier.other168341cs
dc.identifier.urihttp://hdl.handle.net/11012/196698
dc.language.isoencs
dc.publisherIvyspringcs
dc.relation.ispartofTheranosticscs
dc.relation.urihttps://www.thno.org/v11p1546.htmcs
dc.rightsCreative Commons Attribution 4.0 Internationalcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/1838-7640/cs
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/cs
dc.subjectBioavailabilityen
dc.subjectDrug deliveryen
dc.subjectNanotechnologyen
dc.subjectTargeted therapyen
dc.titleNanomedicine of tyrosine kinase inhibitorsen
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-168341en
sync.item.dbtypeVAVen
sync.item.insts2021.05.05 16:54:44en
sync.item.modts2021.05.05 16:14:55en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Chytré nanonástrojecs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Nanomedicine of tyrosine kinase inhibitors.pdf
Size:
2.3 MB
Format:
Adobe Portable Document Format
Description:
Nanomedicine of tyrosine kinase inhibitors.pdf
Download
Collections
Chytré nanonástroje